Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6416 USD | -2.79% | +1.42% | -13.95% |
04/04 | North American Morning Briefing : Focus Turns to -2- | DJ |
04/04 | Traws Pharma, Inc. Announces Chief Executive Office Changes | CI |
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.95% | 13.92M | - | ||
+26.28% | 42.68B | B- | ||
-3.99% | 42.4B | B | ||
+45.32% | 40.04B | A | ||
-6.20% | 28.31B | C | ||
+6.36% | 24.94B | B- | ||
-21.47% | 18.96B | B | ||
+27.58% | 12.3B | C+ | ||
-2.75% | 11.95B | C+ | ||
-2.02% | 11.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- TRAW Stock
- Ratings Traws Pharma, Inc.